Literature DB >> 8634438

Expression of A-myb, but not c-myb and B-myb, is restricted to Burkitt's lymphoma, sIg+ B-acute lymphoblastic leukemia, and a subset of chronic lymphocytic leukemias.

J Golay1, M Luppi, S Songia, C Palvarini, L Lombardi, A Aiello, D Delia, K Lam, D H Crawford, A Biondi, T Barbui, A Rambaldi, M Introna.   

Abstract

The A-myb gene encodes a transcription factor that is related both functionally and structurally to the v-myb oncogene. Following our observations that A-myb is expressed in a restricted subset of normal mature human B lymphocytes, with the phenotype CD38+, CD39-, slgM-, we have now investigated the pattern of A-myb expression in neoplastic B cells representating the whole spectrum of B-cell differentiation and compared it to that of c-myb and B-myb. In a panel of 32 B-cell lines, A-myb was very strongly expressed in most Burkitt's lymphoma (BL) cell lines, but weak or negative in 2 pre-B acute lymphoblastic leukemia (ALL), 4 non-Hodgkin's lymphoma (NHL), 6 Epstein-Barr virus-immortalized lymphoblastoid cell lines, and 6 myeloma lines. Protein expression paralleled that of the RNA. We have also investigated A-myb expression in 49 fresh cases of B leukemias. Among 24 ALL, 6 were of the null and 11 of the common type and all these were negative for A-myb expression; on the other hand, all 7 B-ALL cases (slg+), as well as one fresh BL case with bone marrow infiltration, expressed A-myb. A-myb was undetectable in 4 prolymphocytic leukemias (PLL) but was strongly expressed in 5/20 (25%) of chronic lymphocytic leukemia (CLL) samples. In the latter A-myb did not correlate with phenotype or clinical stage. Finally, we have studied the progression of one case of CLL into Richter's syndrome and have found that the Richter's cells expressed about 25-fold less A-myb RNA than the CLL cells from the same patient. The pattern of c-myb and B-myb was clearly distinct from that of A-myb. C-myb and B-myb were expressed in all neoplastic groups, except in CLL cells. Thus, A-myb expression, unlike that of c-myb and B-myb, is restricted to a subset of B-cell neoplasias (in particular BL and slg+B-ALL) representative of a specific stage of B-cell differentiation. This expression may in part reflect expression of A-myb by the normal germinal center B cells that are the normal counterpart of these transformed B cells. The data presented strongly support a role for this transcription factor in B-cell differentiation and perhaps in B-cell transformation in some neoplasias.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8634438

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

Review 1.  Richter's transformation in chronic lymphocytic leukemia.

Authors:  Apostolia-Maria Tsimberidou; Michael J Keating; William G Wierda
Journal:  Curr Hematol Malig Rep       Date:  2007-10       Impact factor: 3.952

Review 2.  Recent advances in the diagnosis and therapy of Richter's syndrome.

Authors:  Ronan Swords; John Bruzzi; Francis Giles
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

3.  Regulatory domains of the A-Myb transcription factor and its interaction with the CBP/p300 adaptor molecules.

Authors:  V Facchinetti; L Loffarelli; S Schreek; M Oelgeschläger; B Lüscher; M Introna; J Golay
Journal:  Biochem J       Date:  1997-06-15       Impact factor: 3.857

4.  Ectopic expression of A-myb in transgenic mice causes follicular hyperplasia and enhanced B lymphocyte proliferation.

Authors:  S E DeRocco; R Iozzo; X P Ma; R Schwarting; D Peterson; B Calabretta
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

5.  MYBL2 accelerates epithelial-mesenchymal transition and hepatoblastoma metastasis via the Smad/SNAI1 pathway.

Authors:  Meng Wei; Ran Yang; Mujie Ye; Yong Zhan; Baihui Liu; Lingdu Meng; Lulu Xie; Min Du; Junfeng Wang; Runnan Gao; Deqian Chen; Rui Dong; Kuiran Dong
Journal:  Am J Cancer Res       Date:  2022-05-15       Impact factor: 5.942

6.  Alteration of C-MYB DNA binding to cognate responsive elements in HL-60 variant cells.

Authors:  C Gaillard; E Le Rouzic; C Créminon; B Perbal
Journal:  Mol Pathol       Date:  2002-10

Review 7.  Chronic lymphocytic leukaemia: could immunological tolerance mechanisms be the origin of lymphoid neoplasms?

Authors:  Ricardo García-Muñoz; Luis Llorente
Journal:  Immunology       Date:  2014-08       Impact factor: 7.397

Review 8.  Myb proteins: angels and demons in normal and transformed cells.

Authors:  Ye Zhou; Scott A Ness
Journal:  Front Biosci (Landmark Ed)       Date:  2011-01-01

9.  Identification and validation of a two-gene expression index for subtype classification and prognosis in Diffuse Large B-Cell Lymphoma.

Authors:  Qinghua Xu; Cong Tan; Shujuan Ni; Qifeng Wang; Fei Wu; Fang Liu; Xun Ye; Xia Meng; Weiqi Sheng; Xiang Du
Journal:  Sci Rep       Date:  2015-05-05       Impact factor: 4.379

10.  Gene expression-based risk score in diffuse large B-cell lymphoma.

Authors:  Caroline Bret; Bernard Klein; Jérôme Moreaux
Journal:  Oncotarget       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.